Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

NCT02048917 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2020-01-29

No results posted yet for this study

Summary

The purpose of this study is to find an optimal smoking cessation strategy in patients undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky by delivering high quality smoking cessation to all enrolled patients. This study will also examine the feasibility of routinely implementing an array of smoking cessation strategies for this patient population.

Conditions

Interventions

DRUG

High Intensity Counseling + Long Acting NRT + PRN NRT

High Intensity Counseling + Long Acting NRT + PRN NRT

DRUG

High Intensity Counseling + bupropion + PRN NRT

High Intensity Counseling + bupropion + PRN NRT

DRUG

High Intensity Counseling + varenicline + PRN NRT

High Intensity Counseling + varenicline + PRN NRT

DRUG

High Intensity Counseling + Long Acting NRT

High Intensity Counseling + Long Acting NRT

DRUG

High Intensity Counseling + bupropion

High Intensity Counseling + bupropion

DRUG

High Intensity Counseling + varenicline

High Intensity Counseling + varenicline

DRUG

Low Intensity Counseling + Long Acting NRT + PRN NRT

Low Intensity Counseling + Long Acting NRT + PRN NRT

DRUG

Low Intensity Counseling + bupropion + PRN NRT

Low Intensity Counseling + bupropion + PRN NRT

DRUG

Low Intensity Counseling + varenicline + PRN NRT

Low Intensity Counseling + varenicline + PRN NRT

DRUG

Low Intensity Counseling + Long Acting NRT

Low Intensity Counseling + Long Acting NRT

DRUG

Low Intensity Counseling + bupropion

Low Intensity Counseling + bupropion

DRUG

Low Intensity Counseling + varenicline

Low Intensity Counseling + varenicline

Sponsors & Collaborators

  • Kentucky Lung Cancer Research Program

    collaborator OTHER
  • University of Kentucky

    lead OTHER

Principal Investigators

  • Joseph Valentino, M.D. · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-22
Primary Completion
2019-05-15
Completion
2019-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02048917 on ClinicalTrials.gov